TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Fresh Oral Fluid Samples With Known HIV (+) Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HIV Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total measured blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Degree of technical difficulty during liver transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in ADC following bone marrow transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase of Paracentesis/Puncture-free Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcium Levels at Month 3 Post Calcitriol Treatment Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Calcium Levels at Month 3 Post Paricalcitol Treatment Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Negative Symptoms (esp.intrinsic motivation)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 24 hours esophageal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reason for Therapy Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Respiratory Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: POGO score at maximum laryngeal view
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Emotional Functioning - Linear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Emotional Functioning - Quad
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Observer Scar Assessment Scale (POSAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of complaints about device use and operation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Daily awe experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum bactericidal assay responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Path Length (TPL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieving None or Mild on the Investigator's Assessment of Crow's Feet Lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy of MRgFUS in treating painful bone metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patterns of immune abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of the HairDx Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision and reproducibility of HairDx Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RFA or biopsy feasibility rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of a new point shear-wave elastography method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Isotonic Crystalloid Which is 0.9% Saline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Ashworth score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: average duration of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: duration of oxygen therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of BPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Current Opioid Misuse Measure
Endpoint domain: Adverse events/effects
Primary endpoint: Brief Child Abuse Potential Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Patients With Drug-related Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: quality of performed bronchoalveolar lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contribution to diagnosis and/or therapeutic decision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Biopsy Proven Rejections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feeding success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of tegaprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of tegaprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal Bone Level Alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Change in Level of Pain Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Satisfaction With Pain Control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-reported pain and function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The shoulder pain and disability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of active motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic [AUC(0-24)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Days on Sick Leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Immunological biomarker changes in maternal serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oxidative stress biomarker changes in maternal serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hormonal biomarker changes in maternal serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Immunological biomarker changes in placental tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oxidative stress biomarker changes in placental tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hormonal biomarker changes in placental tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Patient utilisation of digital service
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serum Phosphorus Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in laboratory, ECG and vital signs parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in physical or neurological examination findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sustained Virologic Response at Post-treatment Week 12 (SVR12) in Post-liver Transplanted Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response at Post-treatment Week 12 (SVR12) in Cirrhotic Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion to dysplasia or esophageal adenocarcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Spielberger Status Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Well-being Star Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time in range within 6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Natural Log Transformed Area Under the Fluoride Concentration in Plaque Fluid (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence rate of bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: absolute change in percent predicted forced vital capacity (%FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall Response in the Brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Utility and performance of the cystoscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cumulative time that NIRS is below threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum decrease in blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Differences in proteins in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated effect-site propofol concentration at loss of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell numbers of blood samples in VKH patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cell subtype proportion in blood samples in VKH patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cell functional change in VKH patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Mobility Inventory
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: tenofovir pharmacokinetics (PK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tenofovir pharmacodynamics (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IntraOcular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Severe Asthma Questionnaire (SAQ) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presynaptic inhibition level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of oncologists aware of correct indication of Vectibix regarding tumor KRAS status
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of oncologists who conduct a KRAS test prior to initiation of Vectibix treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of oncologists who administer Vectibix in mCRC patients with mutant KRAS tumors or with KRAS status unknown
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post procedural angiographic evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: disease-free survival period
Endpoint domain: Mortality/survival
Primary endpoint: Response rate to weekly vinblastine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of injections
Endpoint domain: Adverse events/effects
Primary endpoint: Mass General Hair Pulling Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mass General Hair Pulling Scale, Actual Pulling Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decreased post-op pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased post-op narcotic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Distance difference of Six-minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plantar Foot Temperature Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete a set amount of work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gut hormones responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Charcot-Marie-Tooth Neuropathy Score (CMTNS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in incidence and severity of acute mountain sickness
Endpoint domain: Adverse events/effects
Primary endpoint: Number of vessels in the umbilical cord at 11 to 13 6/7 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of vessels in the umbilical cord at 18 to 23 6/7 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Electrolyte disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEG-P preparation tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum levels of HSP90 and 70
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety in migraine patients
Endpoint domain: Adverse events/effects
Primary endpoint: Primary care provider utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ED utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Global Health-related quality of life (HRQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Eating restrictions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number and Rate of Participants Recruited into the Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completion of total infusion of ketamine by participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants and providers with positive response to ketamine administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in overnight peritoneal ultrafiltration (UF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in weekly peritoneal Kt/V urea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in weekly peritoneal creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Variation of erythropoietin resistance index (ERI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: IPT Quality and Adherence Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Matsuda insulin sensitivity index (MISI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline cognitive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of level of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Receipt of recommended care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Receipt of recommended medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in the Modified Friedreich Ataxia Rating Scale (mFARS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Confirmed cases of active tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical diagnosis of active tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in food craving levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in sputum cell counts and inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in white blood cell and inflammatory biomarker counts in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to SARS-CoV-2 nasopharyngeal excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants converted to more aggressive treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Resolution of esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: VTE event recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Gastroparesis Cardinal Symptom Index (GCSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Patient Assessment of gastrointestinal disorders-symptom severity index (PAGI-SYM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in G-POEM SF-36 Health Survey score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: intestinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase of cerebral microbleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Side effects and tolerance of first and second line treatments
Endpoint domain: Adverse events/effects
Primary endpoint: Headache Disability Inventory (HDI)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Dizziness Handicap Inventory (DHI)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Platelet activation intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence of clinical thrombotic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of Well-Being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain level measured by Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Alive and Without Progressive Disease at Month 6
Endpoint domain: Mortality/survival
Primary endpoint: Change in time to complete King-Devick Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absence of (Serious) Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of stability of the distal tibiofibular joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of stability of the fracture of the medial malleolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Delirium episode duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of delirium episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triplicate ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Modified Fatigue Impact Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Quadrants With Detected Breast Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of iBE Breast Lesion Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of iBE Breast Lesion Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Grade 2 or higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: SAQ-angina frequency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in mean serum 25OHD levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of treatment related Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to prescribed medication regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Complications following surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Mechanical power values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in ADAS-J cog Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence of stage II posterior wall defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's feelings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity and Specificity of automatic classification in AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady-state concentration (Css)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor response assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in Cancer Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to 100% epithelialization of study ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes